Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation
Identifieur interne : 002512 ( Istex/Curation ); précédent : 002511; suivant : 002513Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation
Auteurs : Elena Moro [Pays-Bas] ; Rianne J. A. Esselink [Pays-Bas] ; Alim Louis Benabid [Pays-Bas] ; Pierre Pollak [Pays-Bas]Source :
- Brain [ 0006-8950 ] ; 2002-11.
English descriptors
- KwdEn :
Abstract
The response to levodopa changes over time in Parkinson’s disease, probably due to alterations in the dopaminergic system, progression of the disease and pulsatile oral intake of the drug. Bilateral high‐frequency stimulation of the subthalamic nucleus (STN) allows a large reduction or the complete cessation of levodopa intake in patients with advanced Parkinson’s disease. We studied variation in the motor short‐duration response (SDR) during a levodopa challenge in bilaterally STN‐stimulated patients. Twenty‐eight consecutive patients with a mean duration of Parkinson’s disease of 16.6 ± 6.0 years at the time of surgery were enrolled. Fourteen patients were evaluated both before STN stimulation and 3 months after surgery (group 1) whereas the other 14 patients were assessed before implantation and after a mean of 3 years of STN stimulation (group 2). After drug withdrawal for one night, the hand‐tapping test (TT) was carried out every 15 min, together with evaluation of dyskinesias using a modified Goetz scale. The Unified Parkinson’s Disease Rating Scale (UPDRS) motor score was assessed every 30 min. In operated patients, STN stimulation was stopped 15 min before starting the clinical evaluations. A suprathreshold oral levodopa dose was given after one motor evaluation and two TTs. The clinical evaluation was carried out until the TT score returned to the baseline. In group 1, six patients continued without levodopa after surgery and the other eight received a daily mean dose of 337 mg; in group 2, seven patients continued without levodopa and the other seven received a daily mean dose of 386 mg. The main change in the levodopa SDR was a significant reduction in levodopa‐induced dyskinesias in both groups. In those patients of group 1 who did not receive levodopa after surgery, the motor UPDRS magnitude decreased and the ‘on’ UPDRS motor score worsened. In group 2, the results were similar, but in the patients who continued to receive levodopa after surgery the TT magnitude increased. On the whole, chronic bilateral STN stimulation tended to decrease the magnitude of the levodopa SDR without changing the duration and latency of the response. These results suggest that continuous STN stimulation induces long‐term plastic changes of the dopaminergic system, with slow and partial desensitization. In addition, the persistence of levodopa intake after surgery might hinder this beneficial process.
Url:
DOI: 10.1093/brain/awf249
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002514
Links to Exploration step
ISTEX:32195035FCE3CBB97AF065117F9C33C82BC31770Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation</title>
<author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Esselink, Rianne J A" sort="Esselink, Rianne J A" uniqKey="Esselink R" first="Rianne J. A." last="Esselink">Rianne J. A. Esselink</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Benabid, Alim Louis" sort="Benabid, Alim Louis" uniqKey="Benabid A" first="Alim Louis" last="Benabid">Alim Louis Benabid</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:32195035FCE3CBB97AF065117F9C33C82BC31770</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1093/brain/awf249</idno>
<idno type="url">https://api.istex.fr/document/32195035FCE3CBB97AF065117F9C33C82BC31770/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002514</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002514</idno>
<idno type="wicri:Area/Istex/Curation">002512</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation</title>
<author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Esselink, Rianne J A" sort="Esselink, Rianne J A" uniqKey="Esselink R" first="Rianne J. A." last="Esselink">Rianne J. A. Esselink</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Benabid, Alim Louis" sort="Benabid, Alim Louis" uniqKey="Benabid A" first="Alim Louis" last="Benabid">Alim Louis Benabid</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences and INSERM U318, Joseph Fourier University, CHU de Grenoble, Grenoble, France, Department of Neurology, Niguarda Ca’ Granda Hospital, Milan, Italy and Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Brain</title>
<title level="j" type="abbrev">Brain</title>
<idno type="ISSN">0006-8950</idno>
<idno type="eISSN">1460-2156</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="volume">125</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="2408">2408</biblScope>
<biblScope unit="page" to="2417">2417</biblScope>
</imprint>
<idno type="ISSN">0006-8950</idno>
</series>
<idno type="istex">32195035FCE3CBB97AF065117F9C33C82BC31770</idno>
<idno type="DOI">10.1093/brain/awf249</idno>
<idno type="local">awf249</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abbreviations: LEDD = levodopa equivalent daily dose; LDR = long‐duration response; SDR = short‐duration response; STN = subthalamic nucleus; TT = tapping test; UPDRS = Unified Parkinson’s Disease Rating Scale</term>
<term>Keywords: levodopa; subthalamic nucleus; deep‐brain stimulation; Parkinson’s disease</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The response to levodopa changes over time in Parkinson’s disease, probably due to alterations in the dopaminergic system, progression of the disease and pulsatile oral intake of the drug. Bilateral high‐frequency stimulation of the subthalamic nucleus (STN) allows a large reduction or the complete cessation of levodopa intake in patients with advanced Parkinson’s disease. We studied variation in the motor short‐duration response (SDR) during a levodopa challenge in bilaterally STN‐stimulated patients. Twenty‐eight consecutive patients with a mean duration of Parkinson’s disease of 16.6 ± 6.0 years at the time of surgery were enrolled. Fourteen patients were evaluated both before STN stimulation and 3 months after surgery (group 1) whereas the other 14 patients were assessed before implantation and after a mean of 3 years of STN stimulation (group 2). After drug withdrawal for one night, the hand‐tapping test (TT) was carried out every 15 min, together with evaluation of dyskinesias using a modified Goetz scale. The Unified Parkinson’s Disease Rating Scale (UPDRS) motor score was assessed every 30 min. In operated patients, STN stimulation was stopped 15 min before starting the clinical evaluations. A suprathreshold oral levodopa dose was given after one motor evaluation and two TTs. The clinical evaluation was carried out until the TT score returned to the baseline. In group 1, six patients continued without levodopa after surgery and the other eight received a daily mean dose of 337 mg; in group 2, seven patients continued without levodopa and the other seven received a daily mean dose of 386 mg. The main change in the levodopa SDR was a significant reduction in levodopa‐induced dyskinesias in both groups. In those patients of group 1 who did not receive levodopa after surgery, the motor UPDRS magnitude decreased and the ‘on’ UPDRS motor score worsened. In group 2, the results were similar, but in the patients who continued to receive levodopa after surgery the TT magnitude increased. On the whole, chronic bilateral STN stimulation tended to decrease the magnitude of the levodopa SDR without changing the duration and latency of the response. These results suggest that continuous STN stimulation induces long‐term plastic changes of the dopaminergic system, with slow and partial desensitization. In addition, the persistence of levodopa intake after surgery might hinder this beneficial process.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002512 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002512 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:32195035FCE3CBB97AF065117F9C33C82BC31770 |texte= Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |